[参考文献][1] SpiritoP,AutoreC.Managementofhypertrophiccardiomyopathy[J].BMJ,2006,332（7552）:1251-1255.[2] MaronBJ,McKennaWJ,DanielsonGK,etal.AmericanCollegeofCardiology/EuropeanSocietyofCardiologyClinicalExpertConsensusDocumentonHypertrophicCardiomyopathy[J].EurHeartJ,2003,24（21）:1965-1991.[3] MaronBJ.Hypertrophiccardiomyopathy:asystematicreview[J].JAMA,2002,287（10）:1308-1320.[4] MaronMS,GohmanTE,CaseySA,etal.Significanceandrelationshipbetweenmagnitudeofleftventricularhypertrophyandcongestiveheartfailuresymptomsinhypertrophiccardiomyopathy[J].JAmCollCardiol,2002,39（supplA）:173.[5] Ostman2SmithI,WettrellG,RiesenfeldT.Acohortstudyofchildhoodhypertrophiccardiomyopathy:improvedsurvivalfollowinghigh2dosebeta2adrenoceptorantagonisttreatment[J].JAmCollCardiol,1999,34（6）:1813-1822.[6] SpiritoP,SeidmanCE,McKennaMJ,etal.Themanagementofhypertrophiccardiomyopathy[J].NEnglJMed,1997,336（11）:775-785.[7] BorjaJ,IzquierdoJ,GuindoJ.Hypertrophiccardiomyopathy:combinationofβblockersandverapamilmayberisky[J].BMJ,2006,333（7558）:97.[8] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会,中国心肌病诊断与治疗建议工作组.心肌病诊断与治疗建议[J].中华心血管病杂志,2007,35（1）:5-16.[9] FiferMA,O′GaraPT,McGovernBA,etal.Effectsofdisopyramideonleftventriculardiastolicfunctioninhypertrophiccardiomyopathy[J].AmJCardiol,1994,74（4）:405.[10] SherridMV,BaracI,McKennaWJ.Multicenterstudyoftheefficacyandsafetyofdisopyramideinobstructivehypertrophiccardiomyopathy[J].JAmCollCardiol,2005,45（8）:1251-1258.[11] HamadaM,ShigematsuY,InabaS,etal.AntiarrhythmicdrugcibenzolineattenuatesleftventricularpressuregradientandimprovestransmitralDopplerflowpatterninpatientswithhypertrophicobstructivecardiomyopathycausedbymidventricularobstruction[J].CircJ,2005,69（8）:940-945.[12] AraujoAQ,ArteagaE,IanniBM.Effectoflosartanonleftventriculardiastolicfunctioninpatientswithnonobstructivehypertrophiccardiomyopathy[J].AmJCardiol,2005,96（11）:1563-1567.[13] KawanoH,TodaG,NakamizoR,etal.ValsartandecreasestypeIcollagensynthesisinpatientswithhypertrophiccardiomyopathy[J].CircJ,2005,69（10）:1244-1248.[14] TsyboulevaN,ZhangL,ChenS,etal.Aldosterone,throughnovelsignalingproteins,isafundamentalmolecularbridgebetweenthegeneticdefectandthecardiacphenotypeofhypertrophiccardiomyopathy[J].Circulation,2004,109（10）:1284-1291.[15] PatelR,NaguehSF,TsyboulevaN,etal.Simvastatininducesregressionofcardiachypertrophyandfibrosisandimprovescardiacfunctioninatransgenicrabbitmodelofhumanhypertrophiccardiomyopathy[J].Circulation,2001,104（3）:317-324.[16] StaufferBL,KonhilasJP,LuczakED,etal.Soydietworsensheartdiseaseinmice[J].JClinInvest,2006,116（1）:209-216.
来源：心血管病学进展作者：陶永康，李一石，樊朝美
